The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.
May 17th 2024
The FDA has approved tarlatamab (Imdelltra; Amgen), a novel bispecific T-cell engager, to treat patients with extensive-stage small cell lung cancer (SCLC).
December 14th 2023
Racial, Ethnic, Socioeconomic Disparities Identified Among Patients With Cachexia at NSCLC Diagnosis
March 15th 2023A recent study identified disparities in cachexia incidence among patients with stage IV non–small cell lung cancer (NSCLC) across different racial, ethnic, and socioeconomic groups.
Read More
Cemiplimab Plus Chemotherapy Approaches EU Approval for PD-L1–Positive NSCLC
March 2nd 2023The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of cemiplimab-rwlc in combination with platinum-based chemotherapy as frontline treatment for adult patients with advanced non–small-cell lung cancer with PD-L1 expression of 1% or higher.
Read More
Targeted Therapies for NSCLC May Be Underused in Medicaid Programs, Study Suggests
January 29th 2023A new study estimates that prescription of standard-of-care non–small-cell lung cancer (NSCLC) therapies is lower than expected in Medicaid programs, with significant variation between states.
Read More
Investigators Find Potential Biomarker for Platinum-Based Chemotherapy Response in NSCLC
January 10th 2023Patients who had non–small cell lung cancer (NSCLC) with homologous recombination gene mutations had better outcomes, although no single gene in the pathway appeared to have a causal role.
Read More
Concurrent Antibiotics, Steroids Raise CDI Risk in People With Lung Cancer Receiving EGFR-TKIs
January 9th 2023The new report found no evidence that second-generation tyrosine kinase inhibitors (TKIs) were more likely to lead to Clostridioides difficile infection (CDI) in patients with lung cancer.
Read More
Tumor-Associated Autoantibodies Demonstrate Promise as Immunotherapy Biomarkers in NSCLC
January 5th 2023The development of 2 panels measuring levels of tumor-associated autoantibodies (TAAbs) has promise for predicting therapeutic response and adverse events for patients with advanced non–small cell lung cancer (NSCLC) after immune checkpoint inhibitor–based treatment.
Read More
Administering Antimicrobial Therapy Before CIT May Be Safer Option in NSCLC
January 5th 2023This study investigated the effects of antimicrobial therapy among patients with non–small cell lung cancer (NSCLC) who received immunotherapy with a checkpoint inhibitor or chemotherapy plus immunotherapy (CIT).
Read More
Dr Hilary Tindle Discusses NMR and Precision Approaches in Cancer Care
December 27th 2022Hilary Tindle, MD, MPH, associate professor of medicine, Vanderbilt University, spoke about the use of precision medicine approaches, such as the nicotine metabolite ratio (NMR), to improve outcomes for patients with lung cancer.
Watch
Dr Davey Daniel Talks Approval of Cemiplimab With Chemotherapy for First-line NSCLC
December 21st 2022Cemiplimab with chemotherapy appears to offer value comparable to other options and may be "an important tool to use" in first-line treatment of non-small cell lung cancer (NSCLC), said Davey Daniel, MD, chief medical officer for OneOncology, lung cancer specialist.
Watch
Cannabis Used With ICIs Appears to Have No Impact on NSCLC Outcomes
December 7th 2022Differences in overall survival between cannabis users and those who did not use the plant were small and could be explained by differences in the make-ups of the 2 cohorts of patients with non-small cell lung cancer, researchers said.
Read More
Despite Improvements in Lung Cancer Screening, Increased Efforts Still Needed to Address Disparities
November 16th 2022The State of Lung Cancer 2022 report issued by the American Lung Association illustrates aspects of diagnosis and care that require additional attention to address disparities and increase nationwide screening and treatment engagement while reducing risk factor exposure.
Read More
Doubling Women’s Lung Cancer Research Funding Would Generate Major Returns, Study Says
November 13th 2022Lung cancer is the number one cause of cancer-related deaths among women in the United States, yet relatively little research funding is spent on the issue, the authors of a new study say.
Read More